PALGESIC RETARD 150 mg PROLONGED-RELEASE TABLETS

Introduction

Package Leaflet: Information for the User

Palgesic Retard 25 mg Prolonged-Release Tablets EFG

Palgesic Retard 50 mg Prolonged-Release Tablets EFG

Palgesic Retard 100 mg Prolonged-Release TabletsEFG

Palgesic Retard 150 mg Prolonged-Release Tablets EFG

Palgesic Retard 200 mg Prolonged-Release Tablets EFG

Palgesic Retard 250 mg Prolonged-Release Tablets EFG

tapentadol

Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.

• Keep this package leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
• If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.

Contents of the Package Leaflet

1. What is Palgesic Retard and what is it used for
2. What you need to know before taking Palgesic Retard
3. How to take Palgesic Retard
4. Possible side effects
5. Storage of Palgesic Retard
6. Contents of the pack and further information

1. What is Palgesic Retard and what is it used for

Tapentadol - the active substance of Palgesic Retard - is a potent analgesic belonging to the class of opioids.

Tapentadol is used for the treatment of severe chronic pain in adults that can only be adequately managed with an opioid analgesic.

2. What you need to know before taking Palgesic Retard

Do not take Palgesic Retard

• if you are allergic to tapentadol or any of the other ingredients of this medication (listed in section 6),
• if you have asthma or if your breathing is slow or shallow to dangerous levels [respiratory depression; hypercapnia (elevated carbon dioxide levels in the blood)],
• if you have a disease in which the intestine does not function properly (paralytic ileus),
• if you have consumed alcohol, sleeping pills, other analgesics, or other psychotropic medications (medications that affect mood and emotions) at high doses (see section "Other medications and tapentadol").

Warnings and precautions

Consult your doctor or pharmacist before starting to take tapentadol:

• if your breathing is slow or shallow,
• if you have increased intracranial pressure or altered consciousness up to coma,
• if you have had a head injury or brain tumors,
• if you have liver or kidney disease (see section "How to take Palgesic Retard"),
• if you have a disease of the pancreas (such as pancreatitis) or bile ducts,
• if you are taking medications called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial opioid agonists (e.g., buprenorphine),
• if you are prone to epilepsy or convulsive seizures, or if you are taking other medications with a known risk of increasing seizures, as the risk of these seizures may increase,
• if you or a family member has a history of substance abuse or dependence on prescription medications or illicit substances ("addiction"),
• if you smoke,
• if you have ever had problems with your mood (depression, anxiety, or personality disorder) or have received psychiatric treatment for other mental illnesses.

This medication contains tapentadol, which is an opioid medication. Repeated use of opioid analgesics can lead to tolerance (you may get used to it) and dependence, which can result in a potentially fatal overdose. It is essential that you inform your doctor if you think you may have developed dependence on tapentadol. Its use (even at therapeutic doses) can cause physical dependence, which may lead to withdrawal symptoms and recurrence of your problems if you stop taking it suddenly.

Tapentadol can cause physical and psychological addiction. If you have a tendency to abuse medications or are dependent on medications, you should only take these tablets for short periods under strict medical supervision.

Sleep-Related Respiratory Disorders

Tapentadol may cause sleep-related respiratory disorders, such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.

Other medications and tapentadol

Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.

The risk of side effects increases if you are taking medications that can cause seizures (attacks), such as certain antidepressants or antipsychotics. The risk of seizures increases if you take tapentadol simultaneously with these medications. Your doctor will tell you if tapentadol is suitable for you.

The concomitant use of tapentadol and sedative medications, such as benzodiazepines or related medications (certain sleeping pills or tranquilizers [e.g., barbiturates] or analgesics like opioids, morphine, and codeine [also as a cough medication], antipsychotics, antihistamines H1, alcohol), increases the risk of somnolence, respiratory difficulties (respiratory depression), coma, and can be potentially fatal. Due to this, concomitant use should only be considered when no other treatment options are possible.

However, if your doctor prescribes tapentadol with sedative medications, they will limit the dose and duration of concomitant treatment.

The concomitant use of opioids and medications used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and can be potentially fatal.

Inform your doctor if you are taking gabapentin or pregabalin or any other sedative medication and follow your doctor's dosage recommendation to the letter. It may be helpful to inform friends or family members so they are aware of the signs and symptoms mentioned above. Contact your doctor when you experience these symptoms.

If you are taking a type of medication that affects serotonin levels (e.g., certain medications for treating depression), talk to your doctor before taking tapentadol, as there have been cases of "serotonin syndrome". Serotonin syndrome is a rare but potentially life-threatening disorder. Symptoms can include involuntary muscle contractions, agitation, excessive sweating, tremors, exaggerated reflexes, increased muscle tone, and body temperature above 38°C. Your doctor can provide you with additional information.

The concomitant administration of tapentadol with other types of medications called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial opioid agonists (e.g., buprenorphine) has not been studied. It is possible that tapentadol may not have the same efficacy if administered with one of these medications. Inform your doctor if you are currently being treated with one of these medications.

The administration of tapentadol with potent inhibitors or inducers (e.g., rifampicin, phenobarbital, St. John's Wort) of certain enzymes necessary for eliminating tapentadol from your body may affect the efficacy of tapentadol or cause side effects, especially when starting or stopping this other type of medication. Keep your doctor informed about all medications you are taking.

Tapentadol should not be taken with MAO inhibitors (medications for treating depression). Inform your doctor if you are taking MAO inhibitors or if you have taken them in the last 14 days.

Taking tapentadol with food, drinks, and alcohol

Do not consume alcohol while taking tapentadol, as some of its side effects, such as somnolence, may increase. The intake of food does not affect the effect of this medication.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Do not take this medication:

• if you are pregnant, unless your doctor has indicated it, as prolonged use of tapentadol during pregnancy may cause withdrawal symptoms in the newborn, which can be life-threatening if not detected and treated by a doctor,
• during labor, as it may cause slow or shallow breathing to dangerous levels (respiratory depression) in the newborn,
• during breastfeeding, as it may be excreted in breast milk.

Driving and using machines

Ask your doctor if you can drive or use machines during treatment with tapentadol. It is essential that you observe how this medication affects you before driving or using machines. Do not drive or use machines if you feel drowsy, dizzy, have blurred vision, or have difficulty concentrating. Be particularly careful when starting treatment, after a dose change, or when taking it concomitantly with alcohol or tranquilizers.

3. How to take Palgesic Retard

Follow the instructions for administration of this medication indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Your doctor will adjust the dose based on the intensity of your pain and your personal sensitivity to pain. Generally, you should take the minimum effective dose to relieve pain.

The tablet can be divided into equal doses.

Adults

The recommended dose is 1 tablet every 12 hours. Daily doses above 500 mg of tapentadol are not recommended.

Your doctor may prescribe a different dose or dosing regimen, which is more suitable for you if necessary. If you think the effect of these tablets is too strong or too weak, consult your doctor or pharmacist.

Elderly patients

In elderly patients (over 65 years of age), the dose does not usually need to be adjusted. However, the elimination of tapentadol may be delayed and slower in some patients in this age group. If this applies to you, your doctor may prescribe a different dosing regimen.

Liver and kidney diseases (hepatic and renal insufficiency)

Patient with severe liver problems should not take these tablets. If you have moderate liver problems, your doctor will prescribe a different dosing regimen. In cases of mild liver problems, no dose adjustment is necessary.

Patient with severe kidney problems should not take these tablets. In cases of mild or moderate kidney problems, no dose adjustment is necessary.

Use in children and adolescents

Tapentadol is not indicated in children and adolescents under 18 years of age.

How and when to take tapentadol

Tapentadol should be taken orally.

Always take the tablets with a sufficient amount of liquid.

You can take the tablets whole or broken in half along the score line. Do not chew or crush them, as this could lead to an overdose because the active substance will be released into your body too quickly.

You can take them on an empty stomach or with food.

The tablet coating may not be completely digested and may appear, apparently unchanged, in the feces. This should not concern you, as the active substance of the tablet will have already been absorbed by the body, and what you see is only the empty coating.

Instructions for opening the blister pack

This medication is packaged in child-resistant, single-dose blister packs. You cannot push the tablet through the blister pack. Please follow the instructions for opening the blister pack:

1. Cut a dose along the pre-cut lines of the blister pack.

1. Locate the non-sealed area where the pre-cut lines intersect.

1. Pull the non-sealed area to peel off the foil

How long to take tapentadol

Do not take the tablets for longer than your doctor has indicated.

If you take more tapentadol than you should

After taking very high doses, you may experience some of the following effects:

• pupils very reduced, vomiting, decreased blood pressure, rapid heartbeat, fainting, altered consciousness or coma (deep loss of consciousness), seizures, slow or shallow breathing to dangerous levels or respiratory arrest.

If any of these things happen to you, call a doctor immediately!

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount used. It is recommended to bring the packaging and the package leaflet of the medication to the healthcare professional.

If you forget to take tapentadol

If you forget to take a tablet, you will probably feel pain again. Do not take a double dose to make up for forgotten doses, but continue taking the tablets as before.

If you stop taking tapentadol

If you stop or discontinue treatment too early, you will probably feel pain again. If you want to stop treatment, consult your doctor before doing so.

Generally, patients do not experience any side effects after stopping treatment, but in rare cases, people who have taken the tablets for a long time may feel unwell if they stop taking them suddenly.

The symptoms may be:

• restlessness, tearful eyes, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils,
• irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, difficulty sleeping, nausea, loss of appetite, vomiting, diarrhea, and increased blood pressure, respiratory rate, or heart rate.

If you experience any of these symptoms after stopping treatment, consult your doctor.

Do not stop taking this medication abruptly, unless your doctor tells you to do so. If your doctor wants you to stop taking these tablets, they will tell you how to do it, which may involve gradually reducing the dose.

If you have any further questions about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medications, this medication can produce adverse effects, although not all people suffer from them.

Adverse effects or important symptoms to be aware of and what to do if you are affected by them:

This medication may cause allergic reactions. Symptoms may include wheezing (a type of whistling when breathing), difficulty breathing, swelling of the eyelids, face, or lips, skin rash, or itching, especially if they affect the whole body.

Another serious adverse effect is breathing more slowly or more weakly than normal. It occurs mostly in elderly patients or weakened patients.

If you present any of these important symptoms, consult your doctor immediately.

Other adverse effects that may occur:

Very frequent(may affect more than 1 in 10 people): nausea, constipation, dizziness, drowsiness, headache.

Frequent(may affect up to 1 in 10 people): decreased appetite, anxiety, depression of mood, difficulty sleeping, nervousness, restlessness, attention disturbances, tremors, muscle twitches, hot flashes, shortness of breath, vomiting, diarrhea, indigestion, itching, increased sweating, skin rashes, feeling of weakness, fatigue, feeling of change in body temperature, dryness of mucous membranes, water accumulation in tissues (edema).

Infrequent(may affect up to 1 in 100 people): allergic reaction to medications (including swelling under the skin, urticarial hives, and in severe cases difficulty breathing, decreased blood pressure, collapse, or shock), weight loss, disorientation, confusion, excitability (agitation), perception disturbances, sleep disturbances, euphoric mood, depression of level of consciousness, memory impairment, mental deterioration, fainting, sedation, balance disorders, speech difficulties, numbness, abnormal sensations in the skin (such as tingling, itching), vision disturbances, accelerated heartbeats, slow heartbeats, palpitations, decreased blood pressure, abdominal discomfort, rash, delayed urination, frequent urination, sexual dysfunction, drug withdrawal syndrome (see section "If you stop treatment with tapentadol"), feeling of discomfort, irritability.

Rare(may affect up to 1 in 1,000 people): drug dependence, thought disturbance, epileptic seizures, feeling of being about to faint, altered coordination, slow or shallow breathing to dangerous levels (respiratory depression), altered gastric emptying, feeling of intoxication, feeling of relaxation.

Frequency not known(cannot be estimated from available data): delirium.

In general, the possibility of having suicidal thoughts and behaviors increases in patients with chronic pain. Additionally, some medications for treating depression (with an impact on the brain's neurotransmitter system) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, experience in patients has not proven that it increases this risk.

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

5. Conservation of Palgesic Retard

Keep this medication out of sight and reach of children.

Do not use this medication after the expiration date that appears on the box and on the blister after CAD. The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Medications should not be thrown away through drains or into the trash. Deposit the containers and medications you no longer need at the SIGRE Point in the pharmacy. Ask your pharmacist how to dispose of the containers and medications you no longer need. This way, you will help protect the environment.

6. Package Contents and Additional Information

Composition of Palgesic Retard

The activeingredient is tapentadol.

Palgesic Retard 25 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 25 mg of tapentadol (in the form of phosphate).

Palgesic Retard 50 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 50 mg of tapentadol (in the form of phosphate).

Palgesic Retard 100 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 100 mg of tapentadol (in the form of phosphate).

Palgesic Retard 150 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 150 mg of tapentadol (in the form of phosphate).

Palgesic Retard 200 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 200 mg of tapentadol (in the form of phosphate).

Palgesic Retard 250 mg prolonged-release tablets EFG

Each prolonged-release tablet contains 250 mg of tapentadol (in the form of phosphate).

The othercomponents (excipients) are:

• Tablet core: microcrystalline cellulose, hypromellose, colloidal anhydrous silica, magnesium stearate.
• Tablet coating: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E 171),

iron oxide red (E172) (only for the 25, 100, 150, 200, and 250 mg doses), iron oxide yellow (E172) (only for the 25, 100, and 200 mg doses), iron oxide black (E172) (only for the 25, 100, 150, 200, and 250 mg doses).

Appearance of Palgesic Retard and Package Contents

Palgesic Retard 25 mg prolonged-release tablets EFG:film-coated brown, oblong, biconvex tablets (5.7 mm x 12.2 mm), with a score on both sides.

Palgesic Retard 50 mg prolonged-release tablets EFG:film-coated white, oblong, biconvex tablets (6.2 mm x 13.2 mm), with a score on both sides.

Palgesic Retard 100 mg prolonged-release tablets EFG:film-coated yellowish, oblong, biconvex tablets (6.7 mm x 14.2 mm), with a score on both sides.

Palgesic Retard 150 mg prolonged-release tablets EFG:film-coated reddish-brown, oblong, biconvex tablets (7.2 mm x 15.2 mm), with a score on both sides.

Palgesic Retard 200 mg prolonged-release tablets EFG:film-coated yellow, oblong, biconvex tablets (7.7 mm x 16.2 mm), with a score on both sides.

Palgesic Retard 250 mg prolonged-release tablets EFG:film-coated brown-red, oblong, biconvex tablets (8.7 mm x 18.2 mm), with a score on both sides.

Available in packages of 60 units, packaged in child-resistant, pre-cut, unit-dose aluminum-PVC/PE/PVDC blisters.

Marketing Authorization Holder

Kern Pharma, S.L.

Venus, 72 - Pol. Ind. Colón II

08228 Terrassa – Barcelona

Spain

Manufacturer

Develco Pharma GmbH

Grienmatt 27

79650 Schopfheim

Germany

Date of the Last Revision of this Prospectus: August 2023

Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)